Numerous institutions are making significant changes in their stakes in
Medtronic PLC (MDT), with several reducing their holdings, while others purchase more shares. Several key financial experts offer differing perspectives with some downgrading their outlook and price targets for
MDT, reflecting concerns about the company's recent performance. However,
Jim Cramer's consistent commendation of the company's operations and management offers optimism. New product launches like the
Stealth AXiS™ Surgical System and partnerships are strengthening
Medtronic's portfolio. Furthermore, the company is gaining momentum in
Diabetes and
Cardiovascular operations, while its MiniMed IPO and FDA approvals for various devices suggest a focus on growth and innovation. On the financial side, despite a lowered outlook, recent earnings reports show strong growth and performance with high revenue growth in the last ten quarters.
Medtronic Plc MDT News Analytics from Tue, 19 Aug 2025 07:00:00 GMT to Sat, 11 Apr 2026 10:54:50 GMT -
Rating 1
- Innovation 5
- Information 7
- Rumor 3
